Cancer Family
Testicular Germ Cell Tumor
CI-CAN-00000362TGCTExplore in graph →
Non-malignant13 active trials
- NCIt
- C8591
- Other
- 1 more code
Loading cancer entity…
Cancer Family
CI-CAN-00000362TGCTExplore in graph →
Clinical trials
115 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06041503 | Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE) | recruiting | Phase 2 | 68 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT05500391 |
| Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring(SUR-CAN) |
| recruiting |
| Phase 2 |
| 88 |
| Centre Oscar LambretOTHER |
| 1 |
| Mar 18, 2026 |
| clinicaltrials |
Data updated 23 days agoSource updated Aug 13, 2026source: clinicaltrials